Drugmakers: Earnings & Pipeline Execution

Focus on medicine developers whose commercial franchises fund clinical pipelines, rather than healthcare distributors or care platforms. Upcoming earnings across the basket create opportunities for prescription demand, launch execution and research progress to differentiate returns from the crowded infrastructure trade. Clinical setbacks, patent competition and disappointing guidance remain material risks. Launch basket (equal weight): MRK, LLY, ABBV, AMGN, MRNA, JNJ, GILD Rules: 1. No inverse, leveraged or volatility ETFs. 2. Only names tradable at the enrolled brokers (Moomoo): no OTC listings, no dead tickers, nothing on the refused list.